论文部分内容阅读
国际制药企业协会联合会(IFP-MA)《鼓励中国新药研发》的专题研究报告指出,只要战略调整得当,中国将很快成为世界新药研发大国。这份报告的负责人是国际制药企业协会联合会前任经济政策总监、现任世界非处方药(OTC)工业协会总监——戴
The IFP-MA “Encouraging China’s R & D of new drugs” report pointed out that China will soon become the world’s new drug R & D center as long as the strategy is properly adjusted. The person in charge of the report is the former director of economic policy of the International Federation of Pharmaceutical Association, the incumbent director of the World Association of Non-Prescription Drugs (OTC) - Dai